Navigation Links
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
Date:5/29/2008

- Fifth cohort of MAD study supports continued development in

treatment-experienced patients -

BRISBANE, Calif., May 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has begun dosing in its Phase 1b clinical trial evaluating ITMN-191, designated R7227 at Roche (SWX: ROG), in combination with Pegasys(R) (pegylated interferon alpha-2a) and Copegus(R) (ribavirin) in treatment-naive patients infected with chronic hepatitis C virus (HCV) genotype 1 infection.

InterMune also reported that results from the only cohort of treatment-experienced patients in its Phase 1b multiple-ascending-dose (MAD) clinical trial of ITMN-191 given as monotherapy support continued development of the compound in treatment-experienced patients. InterMune expects to submit results from all dose cohorts in the MAD study for possible presentation at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

Dan Welch, Chairman and Chief Executive Officer of InterMune, said, "After having recently announced excellent safety and very competitive reductions in serum HCV RNA levels following monotherapy of ITMN-191 in treatment-naive chronic hepatitis C patients, we are pleased to announce the start of our very important 14-day triple combination study of ITMN-191 plus Pegasys and ribavirin, also in treatment-naive patients." He continued, "We are also pleased to report that ITMN-191 given as monotherapy to treatment-experienced patients demonstrated a safety profile and viral kinetic performance that support the continued development of ITMN-191 in this patient population. Based on the monotherapy results to date, we and our partner Roche are planning the develop
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  Giving people with low vision hope ... the International Academy of Low Vision Specialists ... are at the forefront of low vision care. The ... technology and latest treatment options available to patients who ... with traditional means. Recently, doctors in six new states ...
(Date:6/3/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ... immunotherapies, today announced that it has entered into ... purchase approximately $13.6 million of securities in a ... to such investors an aggregate of 2,469,091 shares ... $5.50 per share. The gross ...
(Date:6/3/2015)... The treatment pipeline for Acute ... GBI Research . ... Myeloid Leukemia Therapeutics Market to 2020 - forecasts the ... from $632.6 million in 2013 to $878.6 million by 2020, ... Several drugs to treat AML are expected to be ...
Breaking Medicine Technology:International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 2International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 3International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 4OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 2Novel Acute Myeloid Leukemia Therapies to Offer Clinical Benefit in Small Patient Cohorts 3
(Date:6/3/2015)... EMBARGOED FOR RELEASE UNTIL 2 P.M. ET, WEDNESDAY, ... of Mother’s Home to Gas Wells , PITTSBURGH, June 3, ... of natural gas wells drilled with hydraulic fracturing were more ... living farther from such wells, according to a University ... southwestern Pennsylvania birth records. , The finding does not ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... agreed to pay $7.8 million to resolve a Risperdal ... Arkansas over tactics the company allegedly used to market ... County Circuit Court indicate that the Arkansas Attorney General ... part of the accord. The Risperdal settlement amounts to ...
(Date:6/3/2015)... 2015 Follow us on LinkedIn ... revolutionized disease treatment on account of their better mode ... such as rheumatoid arthritis. The industry is expected to ... small molecule drugs to biopharmaceuticals over the coming years. ... and gene therapies, and recombinant proteins has attracted industry ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Dr. Steven Reisman, ... Cardiac Diagnostic Center ( http://www.newyorkcardiac.com ) located in NYC, announced ... weekdays to his practice. In most cases, depending on the ... the day they call, they will be seen by a ... priority as a cardiologist is to ensure that people who ...
(Date:6/3/2015)... York, NY (PRWEB) June 03, 2015 ... strategic partnership to expand online and mobile access ... Board Review and Maintenance of Certification (MOC) activities. ... will market VeoMed’s innovative courses to Decker’s extensive ... professionals interested in purchasing access to VeoMed’s premier ...
Breaking Medicine News(10 mins):Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 2Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 3Health News:Risperdal Lawsuit News: Johnson & Johnson, Janssen Settle Arkansas Marketing Case for $7.8 Million 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:NYC Cardiologist, Dr. Steven Reisman, Announces Same Day and Evening Appointments 2Health News:VeoMed and Decker Intellectual Properties, the Owner of Scientific American Medicine, Announce a Partnership to Expand Access to Premier Online CME Courses 2
... , Report presents findings by wage ... , , NEW YORK, Sept. 22 ... 15 years, and at a time of heightened economic insecurity, new data ... downward in a number of important areas. The State of Health ...
... , , , SCOTTSDALE, ... "REIT"), a self-managed non-traded real estate investment trust, announced the ... ("GHS") based in Greenville, South Carolina for approximately $162,820,000 on ... is the dominant provider of healthcare services in South Carolina ...
... Washington DC (September 9, 2009) As the economy continues ... effects of the crisis on children,s health, education, and rights ... special issue of the journal Global Social Policy , ... children,s rights and break the cycle of poverty, but also ...
... , , NAPA, Calif., Sept. 21 ... blend, are kicking off the harvest by giving a buck--a buck ... and social issues. Kate & Cassie wines, available exclusively at ... young women. Kate is a mother of three who has ...
... found that switching post-menopausal women with early breast cancer to ... tamoxifen rather than keeping them on tamoxifen for five years ... risk of death for at least the next six years. ... switching to exemestane mid-way through the five-year tamoxifen treatment plan ...
... ... periods or irregular bleeding. Not only does this condition lead to discomfort and embarrassment, it ... don,t know that heavy bleeding is not normal--it is a recognized medical condition for which ... ...
Cached Medicine News:Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 2Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 3Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 4Health News:New Families and Work Institute Study Reveals Declines in the Health of American Workforce 5Health News:Healthcare Trust of America, Inc. Completes Acquisition of 856,000 SF Greenville Hospital System Medical Office Building Portfolio 2Health News:Healthcare Trust of America, Inc. Completes Acquisition of 856,000 SF Greenville Hospital System Medical Office Building Portfolio 3Health News:999: The human face of economic crisis 2Health News:999: The human face of economic crisis 3Health News:KATE AND CASSIE CARE! This Harvest Season, Charity Reaps the Benefits of Kate & Cassie wines 2Health News:Switching early breast cancer patients to exemestane improves long-term survival 2Health News:Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding 2Health News:Endometrial Ablation Offers Relief for Abnormally Heavy or Irregular Menstrual Bleeding 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: